Abstract: Objective  To investigate the application of antiemetic drugs in cancer patients during chemotherapy， so as to provide reference for rational drug use. Methods Clinical data of 533 tumor patients receiving chemotherapy in changhai hospital from June 2016 to May 2017 were retrospectively analyzed， and variables including age， primary tumor diagnosis， chemotherapy regimen and its emetogenic risk， adherence to guidline were collected. In this study， a descriptive statistical analysis was applied on the data of patients receiving single day or multiday chemotherapy regimen， according to NCCN antiemesis guideline. Results  In 533 patients receiving chemotherapy， the proportion of 5-HT3 antagonist preventive antiemetic therapy was 100％. Among them， the guidelines for high risk of vomiting were in accordance with the rate of chemotherapy. The daily chemotherapy was higher than that of the single day chemotherapy， which was 22.29％ and 15.79％ respectively. Conclusion  The prophylactic use of antiemetic drugs in cancer patients is based on 5-HT3 receptor antagonist combined with hormone， and the low compliance rate of antiemetic drug use is associated with the accessibility of aprepitant.

Key words: Chemotherapy induced nausea and vomiting（CINV）, Chemotherapy, 5-HT3 receptor antagonist, NK-1 receptor antagonist